<DOC>
	<DOCNO>NCT00198276</DOCNO>
	<brief_summary>The purpose study study safety efficacy MedPulser Electroporation bleomycin treatment cutaneous subcutaneous focus cancer .</brief_summary>
	<brief_title>Study Using MedPulser Electroporation System With Bleomycin Treat Cutaneous Subcutaneous Cancer</brief_title>
	<detailed_description>Electroporation therapy ( EPT ) tumor-specific ablative treatment modality potential manage local tumor without potentially undesirable side effect systemic chemotherapy agent radiotherapy . Surgical resection cutaneous lesion may lead significant organ dysfunction and/or permanent disfigurement require reconstructive surgery ( i.e . nose , eye area , ear , medial canthus , nasolabial fold , lip , scalp , etc. ) . In contrast , electroporation therapy may offer equivalent disease control conventional surgery lessen need reconstructive surgery . The ability ablate local cutaneous lesion MedPulserÂ® System use conjunction intralesional Bleomycin important new treatment local management recurrent Basal Cell Carcinoma ( BCC ) , recurrent Squamous Cell Carcinoma ( SCC ) , Melanoma , Adenocarcinoma ( i.e . local recurrence breast cancer ) , Merkel Cell Carcinoma Cutaneous Lymphoma solid tumor symptomatic subcutaneous recurrence provide alternative treatment option subject : 1. fail standard treatment ; 2. unwilling unsuitable undergo conventional surgical excision radiation . EPT Bleomycin spar normal tissue use local disease management may preserve organ function and/or appearance relative surgery .</detailed_description>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>1 . The presence recurrent SCC , recurrent BCC , melanoma , adenocarcinoma ( i.e. , local recurrence breast cancer ) , merkel cell carcinoma , cutaneous lymphoma , subcutaneous solid tumor , primary cutaneous tumor must confirm histological examination tissue ( e.g. , biopsy ) sample obtain within 1 month prior patient signing informed consent form study . 2 . Total volume disease treat require dose bleomycin sulfate le 80 unit . 3 . Tumors margin must completely accessible intralesional bleomycin injection EPT applicator electrode . 4 . Age : 18 year old . 5 . Male female . 6 . Men woman childbearing potential must use physician prescribe contraceptive method undergo protocol relate therapy . 7 . Baseline performance status : ECOG 02 Grade 0 : Fully active , able carry predisease performance without restriction . Grade 1 : Restricted physically strenuous activity ambulatory able carry work light sedentary nature , e.g. , light house work , office work . Grade 2 : Ambulatory capable selfcare , unable carry work activity . Up 50 % waking hour . 8 . Life expectancy least 6 month . 9 . Sign write Informed Consent prior receive study procedure treatment . 1 . Subjects tumor suspect involve 50 % great encasement blood vessel measure magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan . 2 . Subjects tumor bone invasion . 3 . Subjects hypersensitivity bleomycin . 4 . Subjects receive exceed total lifetime dose bleomycin great 400 unit . 5 . Subjects significant history emphysema pulmonary fibrosis . 6 . Subjects indwell cardiac pacemaker tolerate period pacemaker turn . 7 . Subjects history uncontrolled cardiac arrhythmia . 8 . Women pregnant , nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>cutaneous</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>MedPulser</keyword>
	<keyword>bleomycin</keyword>
	<keyword>electroporation</keyword>
	<keyword>Cutaneous subcutaneous cancer</keyword>
</DOC>